MedTrace Logo

Incidence of Invasive Pulmonary Aspergillosis in Ventilator-associated Pneumonia

NCT05671328 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 263

Last updated 2025-12-26

No results posted yet for this study

Summary

Mechanically ventilated patients are at risk of developing ventilator-associated pneumonia (VAP). Invasive pulmonary aspergillosis (IPA), the diagnosis of which motivates the implementation of specific treatments, is one of the causes of VAP. The hypothesis of the study is that the incidence of IPA is 12.4%. For each patient presenting with a suspicion of VAP and requiring a bronchoalveolar lavage (BAL), the diagnosis of API will be evaluated by biological examinations performed on blood and BAL. Medical and surgical history as well as clinical and biological data will be collected for 28 days or until discharge from the ICU.

Conditions

  • Ventilator Associated Pneumonia
  • Pulmonary Aspergillosis Invasive

Interventions

OTHER

Biological examinations performed on blood and BAL

Direct examination and culture of BAL Galactomannan in serum and BAL Serum 1,3 beta D glucans Aspergillus PCR in BAL

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • University Hospital, Lille

    lead OTHER

Principal Investigators

  • Saad NSEIR, MD,PhD · University Hospital, Lille

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-28
Primary Completion
2025-07-18
Completion
2025-07-18

Countries

  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05671328 on ClinicalTrials.gov